Karin Eastham - Net Worth and Insider Trading

Karin Eastham Net Worth

The estimated net worth of Karin Eastham is at least $2 Million dollars as of 2024-04-23. Karin Eastham is the Director of Illumina Inc and owns about 10,838 shares of Illumina Inc (ILMN) stock worth over $1 Million. Karin Eastham is the Director of Veracyte Inc and owns about 23,451 shares of Veracyte Inc (VCYT) stock worth over $465,502. Karin Eastham is also the Director of Nektar Therapeutics and owns about 13,033 shares of Nektar Therapeutics (NKTR) stock worth over $17,725. Details can be seen in Karin Eastham's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Karin Eastham has not made any transactions after 2023-03-16 and currently still holds the listed stock(s).

Transaction Summary of Karin Eastham

To

Karin Eastham Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Karin Eastham owns 5 companies in total, including Nektar Therapeutics (NKTR) , Veracyte Inc (VCYT) , and Geron Corp (GERN) among others .

Click here to see the complete history of Karin Eastham’s form 4 insider trades.

Insider Ownership Summary of Karin Eastham

Ticker Comapny Transaction Date Type of Owner
NKTR Nektar Therapeutics 2022-09-13 director
VCYT Veracyte Inc 2023-03-16 director
GERN Geron Corp 2009-03-30 director
PSNL Personalis Inc 2019-09-09 director
ILMN Illumina Inc 2019-01-02 director

Karin Eastham Latest Holdings Summary

Karin Eastham currently owns a total of 3 stocks. Among these stocks, Karin Eastham owns 10,838 shares of Illumina Inc (ILMN) as of January 2, 2019, with a value of $1 Million and a weighting of 72.96%. Karin Eastham owns 23,451 shares of Veracyte Inc (VCYT) as of March 16, 2023, with a value of $465,502 and a weighting of 26.05%. Karin Eastham also owns 13,033 shares of Nektar Therapeutics (NKTR) as of September 13, 2022, with a value of $17,725 and a weighting of 0.99%.

Latest Holdings of Karin Eastham

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ILMN Illumina Inc 2019-01-02 10,838 120.29 1,303,703
VCYT Veracyte Inc 2023-03-16 23,451 19.85 465,502
NKTR Nektar Therapeutics 2022-09-13 13,033 1.36 17,725

Holding Weightings of Karin Eastham


Karin Eastham Form 4 Trading Tracker

According to the SEC Form 4 filings, Karin Eastham has made a total of 0 transactions in Illumina Inc (ILMN) over the past 5 years. The most-recent trade in Illumina Inc is the sale of 5,000 shares on January 2, 2019, which brought Karin Eastham around $1 Million.

According to the SEC Form 4 filings, Karin Eastham has made a total of 6 transactions in Veracyte Inc (VCYT) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Veracyte Inc is the sale of 18,750 shares on March 16, 2023, which brought Karin Eastham around $427,125.

According to the SEC Form 4 filings, Karin Eastham has made a total of 1 transactions in Nektar Therapeutics (NKTR) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Nektar Therapeutics is the sale of 21,267 shares on September 13, 2022, which brought Karin Eastham around $76,774.

Insider Trading History of Karin Eastham

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Karin Eastham Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Karin Eastham Ownership Network

Ownership Network List of Karin Eastham

No Data

Ownership Network Relation of Karin Eastham


Karin Eastham Owned Company Details

What does Nektar Therapeutics do?

Who are the key executives at Nektar Therapeutics?

Karin Eastham is the director of Nektar Therapeutics. Other key executives at Nektar Therapeutics include SVP & General Counsel Mark Andrew Wilson , Chief R&D Officer Jonathan Zalevsky , and director & President & CEO Howard W Robin .

Nektar Therapeutics (NKTR) Insider Trades Summary

Over the past 18 months, Karin Eastham made no insider transaction in Nektar Therapeutics (NKTR). Other recent insider transactions involving Nektar Therapeutics (NKTR) include a net sale of 137,918 shares made by Howard W Robin , a net sale of 62,098 shares made by Jonathan Zalevsky , and a net sale of 46,514 shares made by Mark Andrew Wilson .

In summary, during the past 3 months, insiders sold 36,653 shares of Nektar Therapeutics (NKTR) in total and bought 0 shares, with a net sale of 36,653 shares. During the past 18 months, 276,610 shares of Nektar Therapeutics (NKTR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 276,610 shares.

Nektar Therapeutics (NKTR)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Nektar Therapeutics Insider Transactions

No Available Data

Karin Eastham Mailing Address

Above is the net worth, insider trading, and ownership report for Karin Eastham. You might contact Karin Eastham via mailing address: C/o Burnham Institute For Medical Resear, 10901 N. Torrey Pines Road, La Jolla Ca 92037.

Discussions on Karin Eastham

No discussions yet.